Velcade®
Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma and mantle cell lymphoma. It reversibly inhibits the 26S proteasome.
| Dosage Form | IV / SC Injectable (Lyophilized Powder) |
| Strength | 3.5 mg/vial |
| Storage | Store at 25°C. Reconstituted solution stable for 8 hours at 25°C. |
| Category | Oncology |
| Availability | Available for Transfer |
Multiple myeloma; mantle cell lymphoma (patients who have received at least one prior therapy).
Reversibly inhibits the chymotrypsin-like activity of the 26S proteasome, disrupting protein homeostasis and triggering apoptosis in rapidly dividing cells.
Each Burrard Pharmaceuticals technology transfer package for Bortezomib includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.